The magic of L-dopa

Focus on Parkinson's Disease

Volumn 19, Issue 1, 2007, Pages 2-3

  Lees, Andrew J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE;

ADJUVANT THERAPY; ANKLE EDEMA; BRADYKINESIA; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; CONTINUOUS INFUSION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; DYSKINESIA; EDITORIAL; HUMAN; MENTAL DISEASE; MONOTHERAPY; MOOD DISORDER; MOTOR DYSFUNCTION; NAUSEA; NEUROIMAGING; PARKINSON DISEASE; QUALITY OF LIFE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEADY STATE;

EID: 51749110410     PISSN: 09242015     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (3)

1. Fahn S. A new look at levodopa based on the ELLDOPA study. J Neural Transm Suppl. 2006;70:419-426.
2. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498-2508.
3. Lees AJ, Katzenschlager R, Head J, et al. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology. 2001;57:1687-1694.